Novel Pathways to Manage Inflammation and Atherosclerosis in Dialysis Patients: Role of Nicotinic Acid
Status:
Terminated
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
Patients with kidney failure on hemodialysis have an extremely high rate of cardiovascular
disease including atherosclerotic cardiovascular disease. This, at least in part, is due to
the chronic inflammatory status usually seen in these patients. Here we try to see if
treatment with extended release nicotinic acid (Niaspan) can reduce their overall
inflammatory burden (in general) and the atherosclerotic plaque inflammation (in particular).